A phase II trial of two durations of bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2377-2384

  Sahora, Klaus ^a   Schindl, Martin ^a   Kuehrer, Irene ^a   Eisenhut, Axel ^a   Werba, Gregor ^a   Brostjan, Christine ^a   Telek, Bela ^a   Ba'Ssalamah, Ahmed ^b   Stift, Judith ^b   Schoppmann, Sebastian F ^a   Gnant, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Department of Radiology ^*  (Austria)

Author keywords

Bevacizumab; Gemcitabine; Neoadjuvant therapy; Pancreatic cancer; Resectability

Indexed keywords

BEVACIZUMAB; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; AGED; ANOREXIA; ARTICLE; BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LEUKOPENIA; LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); RADICAL RESECTION; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER EXTREMITY DEEP VEIN THROMBOSIS; ADJUVANT THERAPY; CONTROLLED CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESECTABILITY; TREATMENT OUTCOME; VERY ELDERLY;

BEVACIZUMAB; GEMCITABINE; NEOADJUVANT THERAPY; PANCREATIC CANCER; RESECTABILITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84902960829     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
2. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar N V, Maitra A and Hidalgo M: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29: 4548-4554, 2011.
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, and National Cancer Institute of Canada Clinical Trials G: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007.
4. Heinemann V, Haas M and Boeck S: Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 38: 843-853, 2012.
5. Abbott DE, Baker MS and Talamonti MS: Neoadjuvant therapy for pancreatic cancer: a current review. J Surg Oncol 101: 315-320, 2010.
6. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H and Kleeff J: Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-Analysis of response and resection percentages. PLoS Med 7: e1000267, 2010.
7. Assifi MM, Lu X, Eibl G, Reber HA, Li G and Hines OJ: Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-Analysis of phase II trials. Surgery 150: 466-473, 2011.
8. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Vo n Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
9. Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP and Ghaneh P: Systematic review, including meta-Analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. British journal of cancer 96: 1183-1190, 2007.
10. Eltawil KM, Renfrew PD and Molinari M: Meta-Analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. HPB (Oxford) 14: 260-268, 2012.
11. Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ and Vickers SM: Molecular targeted therapies for pancreatic cancer. Am J Surg 196: 430-441, 2008.
12. Agorogiannis EI and Agorogiannis GI: Coagulation, angiogenesis, and venous thromboembolism in cancer. Lancet 359: 1440, 2002.
13. Hotz HG, Hines OJ, Masood R, Hotz B, Foitzik T, Buhr HJ, Gill PS and Reber HA: VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery 137: 192-199, 2005.
14. Philip PA: Targeting angiogenesis in pancreatic cancer. Lancet 371: 2062-2064, 2008.
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
16. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM and Vokes EE: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23: 8033-8040, 2005.
17. Su Y, Yang WB, Li S, Ye ZJ, Shi HZ and Zhou Q: Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-Analysis of the published literature. PLoS ONE 7: e35629, 2012.
18. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP and investigators As: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. The lancet oncology 14: 1077-1085, 2013.
19. Johnson DR, Leeper HE and Uhm JH: Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Cancer 119: 3489-3495, 2013.
20. Lu DSK, Reber HA, Krasny RM, Kadell BM and Sayre J: Local staging of pancreatic cancer: Criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. American Journal of Roentgenology 168: 1439-1443, 1997.
21. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR and Hwang RF: Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206: 833-846; discussion 846-838, 2008.
22. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB and Wolff RA: Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13: 1035-1046, 2006.
23. Institute NC: National Cancer Institute. Common Terminology Criteria for Adverse Events v.3. NIH publication # 09-7473 2009.
24. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L and Linehan DC: Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16: 1727-1733, 2009.
25. Padhani AR and Ollivier L: The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 74: 983-986, 2001.
26. AJCC: AJCC Cancer Staging Manual 6th Edition. Chicago, Ill: Springer. 2002.
27. Le Scodan R, Mornex F, Partensky C, Mercier C, Valette PJ, Ychou M, Roy P and Scoazec JY: Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial. Am J Clin Oncol 31: 545-552, 2008.
28. Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann SF, Gnant M and Brostjan C: Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. Neoplasia 13: 419-427, 2011.
29. Starlinger P, Brugger P, Reiter C, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann SF, Gnant M and Brostjan C: Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. Neoplasia 13: 980-990, 2011.
30. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676, 2007.
31. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB, 3rd and Eastern Cooperative Oncology Group Study E: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544, 2007.
32. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL and Goldberg RM: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622, 2010.
33. Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, Teleky B, Jakesz R, Peck-Radosavljevic M, Ba'ssalamah A, Zielinski C and Gnant M: NeoGemOx: Gemcita-bine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 149: 311-320, 2011.
34. Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P and Gnant M: NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg 35: 1580-1589, 2011.
35. Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A, Giese NA, Esposito I, Friess H and Kleeff J: The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 6: 1155-1161, 2008.
36. Erkan M, Hausmann S, Michalski CW, Schlitter AM, Fingerle AA, Dobritz M, Friess H and Kleeff J: How fibrosis influences imaging and surgical decisions in pancreatic cancer. Front Physiol 3: 389, 2012.
37. Mahfud M, Breitenstein S, El-Badry AM, Puhan M, Rickenbacher A, Samaras P, Pessaux P, Lopez-Ben S, Jaeck D, Figueras J and Alain-Clavien P: Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg 34: 92-100, 2010.
38. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE and Clary BM: Addition of bevacizumab to irinotecan-And oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206: 96-106, 2008.
39. Tamandl D, Gruenberger B, Klinger M, Herberger B, Kaczirek K, Fleischmann E and Gruenberger T: Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg 252: 124-130, 2010.
40. Borofsky SE, Levine MS, Rubesin SE, Tanyi JL, Chu CS and Lev-Toaff AS: Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients. Abdom Imaging 38: 265-272, 2013.
41. Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM and Cormier JN: Management of bevacizumab-Associated bowel perforation: a case series and review of the literature. Ann Oncol 19: 577-582, 2008.
42. Bergers G and Hanahan D: Modes of resistance to anti-Angiogenic therapy. Nat Rev Cancer 8: 592-603, 2008.
43. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.